Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasms: early-phase trial registry
50 of 160 indexed Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #68 of 28,707 conditions by registered trial count.
160 US clinical trials · 50 currently recruiting · #68 of 28,707 conditions by registered trial count
Neoplasms: 160 US clinical trials tracked, 50 recruiting.
Neoplasms is the subject of 160 registered US clinical trials on ClinicalTrials.gov, 50 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 15 of these trials.
Enrollment posture brief
Registry condition neoplasms
OPEN 50 | RECR 31% | LATE 9 | EARLY 99 | RANK #68 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Aortic Valve Disease (31% recruiting · 16 trials)
Neoplasms lists 50 open slots (31% of 160 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasms is recruiting below its size-band peers.
50 of 160 indexed trials (31.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Neoplasms trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 15 of 160 trials (9.4%). 85 distinct sponsors appear on at least one study for this condition label.
-
Typical Neoplasms enrolment sits around 81 participants.
Median target enrolment is 81 among the 159 trials that report a genuine target (sentinel values excluded). 87 of those (54.7%) plan for fewer than 100 participants.
-
Neoplasms research is mostly interventional.
130 interventional and 30 observational studies make up this index (81.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
160 total, page 4 of 4
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
National Cancer Institute (NCI)
NCT00117013
Self-Management of Cancer-Related Fatigue by Adolescents
Seattle Children's Hospital
NCT00862186
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT00503451
Studying Normal Breast Tissue and Cancer Risk
National Cancer Institute (NCI)
NCT00341692
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
University of Vermont
NCT01004393
To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
Bayer
NCT01028755
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
National Cancer Institute (NCI)
NCT03384316
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
Hoffmann-La Roche
NCT01767623
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
National Institute of Neurological Disorders and Stroke (NINDS)
NCT01222728
A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
Adherex Technologies
NCT00390676
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 81 |
| Phase 2 | 18 |
| Phase 3 | 7 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasms page
160 registered trials, 50 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 50 Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Neoplasms trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasms condition card totals 160 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.